PF-07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID-19 patientsPF-07321332(니르마트렐비르)는 인간 ENT1 또는 ENT2와 상호작용하지 않음: COVID-19 환자에 대한 시사점Article Published on 2022-07-012022-09-11 Journal: Clinical and translational science [Category] COVID19(2023년), SARS, 치료제, [키워드] acute lung injury antivirals bind Biotransformation Clinical efficacy clinical trials contribute coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient death downregulation drug Efficacy EIDD-1931 Emergency use authorization Endothelial cell ENT ENTs expression Factor FDA food greater hypoxia in vitro inhibitor Interaction investigated lung epithelial Lung injury Lungs metabolite molnupiravir Nirmatrelvir nucleoside nucleoside analog nucleoside analogs pandemic Patient patients with COVID-19 PF-07321332 protease Protease inhibitor reflected Remdesivir Replication repression SARS-CoV-2 Severe acute respiratory syndrome shown substrate substrates the SARS-CoV-2 undergo unlikely US Food and Drug Administration viral replication Viral RNA Virology [DOI] 10.1111/cts.13292 PMC 바로가기 [Article Type] Article
Advances in the Omicron variant developmentOmicron 변종 개발의 발전Review Published on 2022-07-012022-09-11 Journal: Journal of internal medicine [Category] COVID19(2023년), SARS, 변종, 진단, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus addition advance Alpha Amino acid amino acids Antiviral antiviral agent Antiviral agents antiviral drugs approved Beta booster dose booster doses Casirivimab circulating coronavirus COVID-19 Delta disease dominant dose drug effective entry of SARS-CoV-2 Epidemiology epitope Epitopes Gamma greater greater transmissibility growth advantage Health Organization humoral Imdevimab Immune escape incidence Infection inhibit Mild mild illness molecular molnupiravir monoclonal monoclonal antibodies monoclonal antibody mutations offer omicron Omicron variant pandemic Paxlovid pharmacological agent pharmacological agents Remdesivir Research respiratory SARS-CoV-2 SARS-CoV-2 virus severe acute respiratory syndrome Coronavirus Spike protein Spread the spike protein therapeutic to define Transmissibility vaccination Vaccine Vaccines variant variants Viral viral replication VoC WHO World Health Organization [DOI] 10.1111/joim.13478 PMC 바로가기 [Article Type] Review
Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2SARS-CoV-2 오미크론 하위 계통 BA.1 및 BA.2에 대한 허가된 단일 클론 항체 및 항바이러스제의 효능Article Published on 2022-06-232022-09-11 Journal: Viruses [Category] COVID19(2023년), SARS, 변종, 진단, 치료제, [키워드] active against agent Antiviral antiviral drugs assays B.1 bamlanivimab Casirivimab cell-based assay Concentration Cytopathic effect defined drug activity etesevimab Evolution of SARS-CoV-2 Ex vivo Imdevimab individual Lineage lineages Live virus mAb mAbs microneutralization Microneutralization assay molnupiravir monoclonal antibodies monoclonal antibody neutralized Neutralizing activity Nirmatrelvir omicron omicron sublineages remained Remdesivir SARS-CoV-2 SARS-CoV-2 variant sera serum dilution SOT Sotrovimab the SARS-CoV-2 treated wild-type [DOI] 10.3390/v14071374 PMC 바로가기 [Article Type] Article
Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral ActivityCOVID-19에 대한 Molnupiravir 용도 변경: 항바이러스 활성 메커니즘Review Published on 2022-06-202022-09-11 Journal: Viruses [Category] COVID19(2023년), SARS, 신약개발, 치료제, [키워드] activity Adults adverse effect Antiviral antiviral activity authorization clinical study clinical trial clinical trials clinical utility complementary COVID-19 COVID-19 severity disrupting Ebola effective Effects Efficacy etiological agent finding generate highlight in vitro experiments in vivo infection with SARS-CoV-2 Influenza mechanism Mild-to-moderate molnupiravir Mutagenesis mutagenic mutated N4-hydroxycytidine NHC Prophylactic repositioning repurposing RNA RNA virus SARS-CoV-2 SARS-CoV-2 replication Treatment viral replication Viral RNA viruses β-d-N4-hydroxycytidine [DOI] 10.3390/v14061345 PMC 바로가기 [Article Type] Review
Synergistic Antiviral Activity of Pamapimod and Pioglitazone against SARS-CoV-2 and Its Variants of ConcernSARS-CoV-2 및 우려 변종에 대한 파마피모드 및 피오글리타존의 상승적 항바이러스 활성Article Published on 2022-06-202022-09-11 Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] acting activity agonist Alpha Anti-inflammatory antiviral activity antiviral potency approved Arthritis assumption Beta cell type cellular cellular pathway cellular targets clinical study clinically evaluated Combination components concern coronavirus COVID-19 COVID-19 patients Delta described diabetes drug effective evaluated Gamma in vitro inhibit SARS-CoV-2 inhibitor kinase mitogen mitogen-activated protein kinase molnupiravir omicron p38-inhibitor pamapimod pathway Paxlovid pioglitazone polymerase potential therapy PPRy-agonist Protease inhibitor protein kinase public health threat reduce Replication replication of SARS-CoV-2 rheumatoid arthritis SARS-CoV-2 SARS-CoV-2 pandemic SARS-CoV-2 replication selective Severity of disease small molecule Small molecules Support synergistic These data transmitted treat Treatment type 2 diabetes Vaccine-induced immunity variant variants variants of concern viral replication virulent virus variants VOCs Wuhan [DOI] 10.3390/ijms23126830 PMC 바로가기 [Article Type] Article
Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters Research Published on 2022-06-152022-10-05 Journal: Nature Microbiology [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] acute respiratory syndrome addition Affect Antigen Antiviral Antiviral compound B.1.1.529 coronavirus effective Efficacy hamster hamsters inhibited inhibitor lung Lungs mAb mAbs molnupiravir monoclonal antibody Mutation omicron Patient protective immune response reduced Replication RNA-dependent RNA polymerase S309 SARS-CoV-2 SARS-CoV-2 protease Spike protein tested therapeutic Treatment variant variants virus replication [DOI] 10.1038/s41564-022-01170-4 [Article Type] Research
COVID-19 update: NIH recommends against ivermectinArticle Published on 2022-06-132023-07-09 Journal: The Medical letter on drugs and therapeutics [Category] COVID19(2023년), [키워드] bebtelovimab COVID-19 Efficacy Ivermectin Lagevrio molnupiravir Nirmatrelvir Paxlovid Remdesivir Ritonavir Veklury
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like ProteaseSARS-CoV-2 파파인 유사 프로테아제 표적화의 진행 상황 및 과제Review Published on 2022-06-092022-09-11 Journal: Journal of medicinal chemistry [Category] Coronavirus, COVID19(2023년), SARS, 변종, 치료제, [키워드] addition Antiviral antiviral drug target approval approved causative agent challenge class cleavage clinic combating COVID-19 pandemic Encouraging highlight Host include inhibitor inhibitors innate immune response knowledge mechanism modulate molnupiravir Nirmatrelvir offer pandemic Papain-like protease pharmacokinetic polymerase polyprotein Progress Protease inhibitor Remdesivir Ritonavir SARS-CoV-2 structure-based design targeting the SARS-CoV-2 U.S. FDA Vaccine variant variants viral infection [DOI] 10.1021/acs.jmedchem.2c00303 PMC 바로가기 [Article Type] Review
What impact can molnupiravir have on the treatment of SARS-CoV-2 infection?몰누피라비르가 SARS-CoV-2 감염 치료에 어떤 영향을 미칠 수 있습니까?Editorial Published on 2022-06-012022-09-11 Journal: Expert opinion on pharmacotherapy [Category] COVID19(2023년), SARS, 치료제, [키워드] Abstract antivirals coronavirus COVID-19 molnupiravir pharmacotherapy SARS-CoV-2 Treatment [DOI] 10.1080/14656566.2022.2057795 PMC 바로가기 [Article Type] Editorial
Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro다양한 용도 변경 약물과 결합된 몰누피라비르는 시험관 내 인간 비강 상피에서 SARS-CoV-2 감염을 추가로 억제합니다Article Published on 2022-06-012022-09-11 Journal: Biomedicine & pharmacotherapy = Biomédecine & phar [Category] COVID19(2023년), SARS, 변종, 신약개발, 치료제, [키워드] accelerated acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Air-liquid interface antiviral activity Antiviral treatment antiviral treatments antivirals caused cellular Clinical efficacy clinical testing clinically Combination combinations complex Compound Concentration coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 drug drug combination drug combinations Drug repurposing effective effective antiviral treatment effort Emergency use evaluated highlighting identify Immunity in vitro in vitro model inhibit inhibiting molnupiravir nasal epithelium Potential treatment Repurposed drug SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 replication selected severe acute respiratory syndrome Coronavirus short duration tested the vaccine These data Treatment Vaccine variant worldwide pandemic [DOI] 10.1016/j.biopha.2022.113058 PMC 바로가기 [Article Type] Article